A multicenter phase II study of sorafenib in Japanese patients with hepatocellular carcinoma and Child Pugh A or B cirrhosis.
Eiichiro Suzuki
No relevant relationships to disclose
Shuichi Kaneko
No relevant relationships to disclose
Takuji Okusaka
Consultant or Advisory Role - Bayer (U)
Honoraria - Bayer
Research Funding - Bayer
Masafumi Ikeda
Honoraria - Taiho Pharmaceutical
Kensei Yamaguchi
No relevant relationships to disclose
Michihisa Moriguchi
No relevant relationships to disclose
Tosiya Sato
No relevant relationships to disclose
Junji Furuse
Consultant or Advisory Role - Bayer (U)
Research Funding - Bayer